Drug intelligence / Profile preview

N-Methyl-N-(Methylbenzyl)Formamide

Development stage: Unknown
Modality: Small Molecules

Overview

N-Methyl-N-(Methylbenzyl)Formamide is a synthetic small molecule with the molecular formula C10H13NO and a molecular weight of 163.22 g/mol. It is classified as an experimental compound and has not been approved for any therapeutic use in the United States or elsewhere. The compound exhibits properties typical of formamides, including stability under normal conditions but susceptibility to hydrolysis under acidic or basic environments[3]. According to DrugBank, it has been identified as a renin inhibitor, suggesting potential activity against the renin enzyme involved in blood pressure regulation[2]. However, there are no clinical trials or approved indications for this molecule.

Other names: N-methyl-N-[(1S)-1-phenylethyl]formamideN-methyl-N-((1S)-1-phenylethyl)formamide

Targets

REN (Renin)

Beyond the preview

Go deeper on N-Methyl-N-(Methylbenzyl)Formamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-Methyl-N-(Methylbenzyl)Formamide.

Explore the full profile